Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | CTSS | P25774 | 6/20 | 0.48 |
| ▸ | CTSK | P43235 | 5/20 | 0.48 |
| ▸ | CTSL | P07711 | 1/20 | 0.47 |
| ▸ | CTSB | P07858 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.46 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.46 |
| ▸ | ACE | P12821 | 1/20 | 0.45 |
| ▸ | ACACB | O00763 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | PPARA | Q07869 | 2/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3676162 | 0.87 | NPC1 (0.63) | ATMCTSSCTSKCTSLCTSB | |
| SCHEMBL29401299 | 0.87 | NPC1 (0.63) | ATMCTSSCTSKCTSLCTSB | |
| SCHEMBL12203694 | 0.87 | NPC1 (0.63) | ATMCTSSCTSKCTSLCTSB | |
| SCHEMBL3676166 | 0.87 | NPC1 (0.63) | ATMCTSSCTSKCTSLCTSB | |
| SCHEMBL4276615 | 0.87 | CTSS (0.49) | ATMCTSSCTSKCTSLCTSB | |
| SCHEMBL3621416 | 0.87 | CTSS (0.49) | ATMCTSSCTSKCTSLCTSB | |
| SCHEMBL7622841 | 0.86 | ACACB (0.56) | ATMCTSSCTSKCTSLCTSB | |
| SCHEMBL2742779 | 0.85 | ACACB (0.54) | ATMCTSSCTSKCTSLCTSB | |
| SCHEMBL13446081 | 0.85 | CTSS (0.60) | ATMCTSSCTSKCTSLCTSB | |
| SCHEMBL14588983 | 0.85 | ACACB (0.54) | ATMCTSSCTSKCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7241810-B2 | Formamide derivatives for the treatment of diseases | PFIZER INC (US) | 2007-07-10 | — | — | US | disclosed |
| US-20050215590-A1 | Formamide derivatives for the treatment of diseases | PFIZER LIMITED (GB) | 2005-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215590-A1 | Formamide derivatives for the treatment of diseases | FH, FAH, HRH4 | ATM 3559/4885CTSS 823/4885CTSK 1325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.